EUVIMEDEUVIMED entdecken
Crossref

A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system

Advaitaa Ravipati iD, Tejus Pradeep, Antonella Tosti

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Advaitaa Ravipati und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata (AA) is an autoimmune condition that leads to patchy, nonscarring hair loss. Its etiology remains unknown; the condition can be debilitating for patients, impacting their psychosocial wellbeing. Various triggers have been reported, ranging from genetic predisposition and infections to environmental factors. Medications have also been thought to be an inciting factor in AA.

Methods

Using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), all cases reporting AA as an adverse event were used to capture associated medications and patient characteristics.

Results

There were 1,331 AA cases reported as an adverse event with medication use. Monoclonal antibodies accounted for 6 out of the top 10 drugs associated with the highest number of AA cases. Males were more likely to report AA when taking adalimumab (OR: 1.79, P = 0.04) and dupilumab (OR: 2.56, P = 0.03) compared to females. Individuals between 42 and 64 years old accounted for 46.7% of AA cases. Lastly, females in older age groups showed greater odds of developing AA compared to males (OR: 1.03, P < 0.01).

Conclusions

Based on the FAERS, there has been a steady rise in AA cases, and monoclonal antibodies were the most frequently cited medication class tied to AA. With a dearth of literature on triggers and patient demographics, we sought to describe features of AA cases that could increase awareness and be used to improve future clinical outcomes in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataUnited StatesMaleFemaleHumansAgedAdultMiddle AgedCross-Sectional StudiesUnited States Food and Drug AdministrationAlopeciaAntibodies, Monoclonal

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA.

ORCID-Profile: Advaitaa Ravipati

Zitieren

APA

Ravipati, A., Pradeep, T., & Tosti, A. (2024). A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system. International Journal of Dermatology. https://doi.org/10.1111/ijd.17014

Vancouver

Ravipati A, Pradeep T, Tosti A. A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system. International Journal of Dermatology. 2024. doi:10.1111/ijd.17014

BibTeX
@article{Ravipati2024,
  author = {Ravipati, Advaitaa and Pradeep, Tejus and Tosti, Antonella},
  title = {A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17014}
}
Kostenlos starten →